Eliem Therapeutics is a clinical-stage biotechnology company.
Our focus is to advance the clinical development of assets for the treatment of hyperexcitability disorders, such as chronic pain. Patients desperately need access to safe, efficacious, and well-tolerated non-opioid therapies to remedy chronic pain. Drugs currently prescribed for pain relief have limited efficacy in addition to tolerability and safety issues, which severely limit their therapeutic benefit.
We will leverage our world-class expertise in neuroscience, translational medicine, and clinical development to address this unmet medical need with a highly innovative pipeline.
Eliem Therapeutics is pioneering a new generation of analgesics to facilitate a better quality of life for patients.
Board of Directors
Contact us for more information: